FindTrial
Sign In

A prospective, open label, monocenter trial to evaluate the interaction between the Platelia Aspergillus ELISA test and the administration of piperacillin/tazobactam.

A prospective, open label, monocenter trial to evaluate the interaction between the Platelia Aspergillus ELISA test and the administration of piperacillin/tazobactam.

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
EU CTR
Registry ID
EUCTR2004-001321-25-IT
Enrollment
Unknown
Registered
2004-07-16
Start date
2004-05-19
Completion date
Unknown
Last updated
2012-03-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Evaluation of interference between platelia aspergillus ELISA TEST and administration of PIPERACILLIN/TAZOBACTAM. MedDRA version: 6.1 Level: HLGT Classification code 10004018

Interventions

Trade Name: Tazocin ev 1fl 4g/0,500g Product Name: piperacillina sodica/tazobactam Pharmaceutical Form: Powder for infusion* INN or Proposed INN: PIPERACILLINA (DC.IT) . CAS Number: 61-47

Sponsors

WYETH LEDERLE
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: Are the trial subjects under 18? no Number of subjects for this age range: F.1.2 Adults (18-64 years) yes F.1.2.1 Number of subjects for this age range F.1.3 Elderly (>=65 years) yes F.1.3.1 Number of subjects for this age range

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

MeasureTime frame
Main Objective: ;Secondary Objective: ;Primary end point(s):—

Countries

Italy

Outcome results

None listed

Source: EU CTR (via WHO ICTRP) · Data processed: Feb 4, 2026